BIOSIMILAR ERYTHROPOIETIN ALFA FOR THE THERAPY OF ANEMIA IN "LOWER RISK" MYELODYSPLASTIC SYNDROMES. INTERIM RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY OF THE "RETE EMATOLOGICA LOMBARDA" (EPOREL)

被引：0
|
作者：
Pelizzari, A. M. [1 ]
Borlenghi, E. [1 ]
Mariotti, J. [2 ]
Riva, M. [3 ]
Molteni, A. [4 ]
Lambertenghi, D. [5 ,6 ]
Passi, A. [1 ]
Orlando, V. [1 ]
Lamorgese, C. [1 ]
Morra, E. [3 ]
机构：
[1] Asst Spedali Civili Brescia, Hematol, Brescia, Italy
[2] Asst Treviglio Caravaggio, Hematol & Transfus Unit, Bergamo, Italy
[3] O Niguarda Ca Granda, Hematol, Milan, Italy
[4] Osped Niguarda Ca Granda, Hematol, Milan, Italy
[5] Asst SS Paolo & Carlo, Med 3, Milan, Italy
[6] Univ Milan, Milan, Italy
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1924
引用
收藏
页码：775 / 775
页数：1
相关论文
共 15 条
  • [1] INTERIM RESULTS FROM A PROSPECTIVE OBSERVATIONAL STUDY OF THE "RETE EMATOLOGICA LOMBARDA" (EPOREL1) ON THE USE OF BIOSIMILAR ERYTHROPOIETIN ALFA (HX575) FOR THE TERAPY OF ANEMIA IN "LOWER RISK" MYELODYSPLASTIC SYNDROMES
    Pelizzari, A. M.
    Schieppati, F.
    Borlenghi, E.
    Riva, M.
    Molteni, A.
    Mariotti, J.
    Lambertenghi, D.
    Scume, M.
    Orlando, V.
    Rossi, G.
    Morra, E.
    HAEMATOLOGICA, 2017, 102 : 41 - 41
  • [2] Treatment of Anemia with Darbepoetin Alfa in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndromes. Results from the ARAMYS Study
    Villegas, Ana
    Arrizabalaga, B.
    Fernandez-lago, C.
    Mouzo, M.
    Mayans, Jr
    Gonalez-Porras, Jr
    Duarte, Rafael
    Remacha, Angel Francisco
    Luno, Elisa
    Gasquet, J. A.
    BLOOD, 2008, 112 (11) : 1184 - 1184
  • [3] EFFECT OF RECOMBINANT HUMAN ERYTHROPOIETIN A ON CARDIAC REMODELING IN PATIENTS WITH "LOW RISK" MYELODYSPLASTIC SYNDROMES: RESULTS FROM A PROSPECTIVE STUDY
    Del Corso, L.
    Rosa, G. M.
    Berisso, G.
    Bianco, D.
    Calzamiglia, T.
    Ghione, P.
    Ghio, R.
    Goretti, F.
    Molinari, E.
    Racchi, O.
    Scudelletti, M.
    Tassara, R.
    Arboscello, E.
    HAEMATOLOGICA, 2015, 100 : 165 - 166
  • [4] IMPACT OF ANEMIA ON HEALTH-RELATED QUALITY-OF-LIFE AND CARDIAC REMODELING IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS). RESULTS OF GLOBQOL OBSERVATIONAL PROSPECTIVE STUDY.
    Ramos, F.
    Pedro, C.
    Tormo, M.
    de Paz, R.
    Font, P.
    Luno, E.
    Caballero, M.
    Solano, F.
    Almagro, M.
    Xicoy, B.
    Jimenez, M.
    HAEMATOLOGICA, 2014, 99 : 215 - 216
  • [5] A 36-month analysis of treatment patterns and outcomes in patients with lower-risk myelodysplastic syndromes from a prospective observational study.
    Lyons, Roger M.
    Marek, Billie J.
    Paley, Carole S.
    Esposito, Jason
    Garbo, Lawrence E.
    DiBella, Nicholas J.
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study
    Balleari, E
    Rossi, E
    Clavio, M
    Congiu, A
    Gobbi, M
    Grosso, M
    Secondo, V
    Spriano, M
    Timitilli, S
    Ghio, R
    ANNALS OF HEMATOLOGY, 2006, 85 (03) : 174 - 180
  • [7] Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study
    Enrico Balleari
    Edoardo Rossi
    Marino Clavio
    Angela Congiu
    Marco Gobbi
    Marco Grosso
    Vincenzo Secondo
    Mauro Spriano
    Silvana Timitilli
    Riccardo Ghio
    Annals of Hematology, 2006, 85 : 174 - 180
  • [8] Recombinant Human Erythropoietin Combined with All-Trans Retinoic Acid and Testosterone Undecanoate in the Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndromes: Updated Results of a Multicenter, Single-Arm, Prospective Trial
    Mei, Chen
    Xie, Yaping
    Shao, Yanping
    Ge, Zheng
    Tong, Hongyan
    BLOOD, 2023, 142
  • [9] PROFILING PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES WHO PREFER TO RECEIVE SURVIVAL PROGNOSTIC INFORMATION. FINAL RESULTS FROM A LARGE INTERNATIONAL PROSPECTIVE COHORT OBSERVATIONAL STUDY
    Efficace, F.
    Gaidano, G.
    Breccia, M.
    Voso, M.
    Caocci, G.
    Stauder, R.
    Angelucci, E.
    Selleslag, D.
    Sanpaolo, M.
    Platzbecker, U.
    Jonasova, A.
    Rauzy, B.
    Buccisano, F.
    Ricco, A.
    Palumbo, G.
    Bowen, D.
    Nguyen, K.
    Niscola, P.
    Huiyong, Z.
    Wan, C.
    Luebbert, M.
    Fenu, S.
    Molica, S.
    Balduini, C.
    Focan, C.
    Ciceri, F.
    Renzo, N.
    Chie, W.
    Ackroyd, S.
    Lunghi, M.
    Klimek, V.
    Cottone, F.
    Vignetti, M.
    Mandelli, F.
    HAEMATOLOGICA, 2013, 98 : 443 - 444
  • [10] Health-Related Quality of Life of Luspatercept Versus Epoetin Alfa in Red Blood Cell Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Results from the Final Datacut of the Phase 3 COMMANDS Study
    Oliva, Esther Natalie
    Platzbecker, Uwe
    Porta, Matteo Giovanni Della
    Garcia-Manero, Guillermo
    Santini, Ualeria
    Fenaux, Pierre
    Shortt, Jake
    Komrokji, Rami S.
    Pelligra, Christopher G.
    Guo, Shien
    Yucel, Aylin
    Glassberg, Mrudula B.
    Eliason, Laurie
    Hnoosh, Ahmed
    Miteva, Dimana
    Rose, Shelo
    Santiri, Valeria
    Kreitz, Sandra
    Sekeres, Mikkael A.
    Zeidan, Amer M.
    BLOOD, 2024, 144 : 3217 - 3218
12